Research programme: hearing disorder therapies - AudioCure Pharma

Drug Profile

Research programme: hearing disorder therapies - AudioCure Pharma

Alternative Names: AC-002; AC-102; AC-103; AC-104

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AudioCure Pharma
  • Class Small molecules
  • Mechanism of Action Adenosine triphosphatase stimulants; Antioxidants; Apoptosis inhibitors; Brain-derived neurotrophic factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hearing disorders

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Hearing disorders in Germany (Intratympanic, Injection)
  • 22 May 2017 AudioCure plans a phase I trial for Hearing disorders in Germany
  • 17 Jan 2014 Preclinical trials in Hearing disorders in Germany (Intratympanic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top